20 percent more patients were treated with proton therapy in 2019

An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam.

An individual eye shield is made for each patient to protect the surrounding tissue from the proton beam. © HZB

Number of patients who received the proton therapy offered jointly by Charité and HZB.

Number of patients who received the proton therapy offered jointly by Charité and HZB. © HZB/J. Politt

For more than 20 years, Charité - Universitätsmedizin Berlin and the Helmholtz-Zentrum Berlin (HZB) have jointly offered the irradiation of eye tumors with protons. In 2019, more patients were treated in Berlin-Wannsee than ever before. 276 patients - 20 percent more than in the previous year - underwent proton therapy. The treatment is specialized in choroidal melanomas of the eye. The proton accelerator at HZB is the only treatment facility for this disease in Germany. 

500 to 600 people in Germany are affected by a malignant choroidal melanoma every year. In 97 percent of cases, the tumour can be completely destroyed by irradiation with protons. In most cases, not only the eye but also the vision can be maintained to a satisfactory degree. "The energy of the proton beam can be adjusted in such a way that practically only the tumor receives the radiation. Since the protons have a straight trajectory, the lateral scattering is much less than with X-rays," explains Dr. Jens Heufelder, the senior medical physicist at Charité - Universitätsmedizin Berlin. The protons effectively destroy the tumor, while the surrounding healthy tissue is largely spared.

To cope with the increase in patients in 2019, treatment operations at the proton accelerator have been extended to 12 hours. Approximately 45 percent of the patients came from the Berlin-Brandenburg region, the other patients came from other German states and other European countries (approximately 8 percent). The youngest patient who received proton therapy at HZB in 2019 was 8 years old, the oldest patient 96 years old. The average age was 61 years.

Since 1998, more than 3,700 patients have been treated with protons from the HZB accelerator. "The success of proton therapy is based on the collaboration between ophthalmologists, medical physicists and accelerator experts. As a result, the therapy has been continuously improved for the benefit of patients over the past few years", explains Prof. Dr. Andrea Denker, head of proton therapy at HZB. 

(sz)

You might also be interested in

  • New monochromator optics for tender X-rays
    Science Highlight
    30.11.2022
    New monochromator optics for tender X-rays
    Until now, it has been extremely tedious to perform measurements with high sensitivity and high spatial resolution using X-ray light in the tender energy range of 1.5 - 5.0 keV. Yet this X-ray light is ideal for investigating energy materials such as batteries or catalysts, but also biological systems. A team from HZB has now solved this problem: The newly developed monochromator optics increase the photon flux in the tender energy range by a factor of 100 and thus enable highly precise measurements of nanostructured systems. The method was successfully tested for the first time on catalytically active nanoparticles and microchips.
  • Nanodiamonds can be activated as photocatalysts with sunlight
    Science Highlight
    30.11.2022
    Nanodiamonds can be activated as photocatalysts with sunlight
    Nanodiamond materials have potential as low-cost photocatalysts. But until now, such carbon nanoparticles required high-energy UV light to become active. The DIACAT consortium has therefore produced and analysed variations of nanodiamond materials. The work shows: If the surface of the nanoparticles is occupied by sufficient hydrogen atoms, even the weaker energy of blue sunlight is sufficient for excitation. Future photocatalysts based on nanodiamonds might be able to convert CO2 or N2 into hydrocarbons or ammonia with sunlight.
  • European pilot line for innovative photovoltaic technology based on tandem solar cells
    News
    23.11.2022
    European pilot line for innovative photovoltaic technology based on tandem solar cells
    PEPPERONI, a four-year Research and Innovation project co-funded under Horizon Europe and jointly coordinated by Helmholtz-Zentrum Berlin and Qcells, will support Europe in reaching its renewable energy target of climate neutrality by 2050. The project will help advance perovskite/silicon tandem photovoltaics (PV) technology’s journey towards market introduction and mass manufacturing.